Quantcast
Connect with us

Ex-hedge funder buys rights to AIDS drug and raises price from $13.50 to $750 per pill

Published

on

A former hedge fund manager turned pharmaceutical businessman has purchased the rights to a 62-year-old drug used for treating life-threatening parasitic infections and raised the price overnight from $13.50 per tablet to $750.

WATCH: Ex-hedge funder who hiked AIDS pill cost by 5,500 percent says drug ‘still underpriced’

According to the New York Times, Martin Shkreli, 32, the founder and chief executive of Turing Pharmaceuticals, purchased the rights to Daraprim for $55 million on the same day that Turing announced it had raised $90 million from Shkreli and other investors in its first round of financing.

ADVERTISEMENT

RELATED: These 37 tweets show how the pharma CEO gouging AIDS patients is even worse than you think

Daraprim is used for treating toxoplasmosis — an opportunistic parasitic infection that can cause serious or even life-threatening problems in babies and for people with compromised immune systems like AIDS patients and certain cancer patients — that sold for slightly over $1 a tablet several years ago.  Prices have increased as the rights to the drug have been passed from one pharmaceutical company to the next, but nothing like the almost 5,500 percent increase since Shkreli acquired it.

Worrying that the cost of treatment could devastate some patients, Dr. Judith Aberg, the chief of the division of infectious diseases at the Icahn School of Medicine at Mount Sinai asked, “What is it that they are doing differently that has led to this dramatic increase?”

According to Shkreli, Turing will use the money it earns to develop better treatments for toxoplasmosis, with fewer side effects.

“This isn’t the greedy drug company trying to gouge patients, it is us trying to stay in business,” Shkreli explained, saying that many patients use the drug for far less than a year and that the new price is similar to other drugs used for rare diseases.

ADVERTISEMENT

Shrkeli also defended his small pharmaceutical company saying, “It really doesn’t make sense to get any criticism for this.”

This is not the first time the fledgling pharmaceutical executive has come under scrutiny.

He started the hedge fund MSMB Capital while in his 20’s and was accused of urging the FDA to not approve certain drugs made by companies whose stock he was shorting.

ADVERTISEMENT

In 2011,  Shkreli helped form Retrophin, which also acquired old drugs and immediately raised their prices. Retrophin’s board fired Shkreli a year ago and has filed a complaint in Federal District Court, accusing him of using Retrophin as a personal fund to pay back angry investors in his hedge fund.

 As for Shrkeli’s claim that he will put the excess profits back into research, doctors say that isn’t needed in this case.

ADVERTISEMENT

“I certainly don’t think this is one of those diseases where we have been clamoring for better therapies,” said Dr. Wendy Armstrong, professor of infectious diseases at Emory University in Atlanta.

Tweet from Martin Shkreli’s Twitter account below:

ADVERTISEMENT


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Breaking Banner

Here’s why Trump contradicted his own White House on the Supreme Court rulings

Published

on

Following the Supreme Court's pair of 7-2 decisions rejecting President Donald Trump's claim to have absolute immunity from subpoenas, he blasted the ruling on Twitter, claiming he being unfairly targeted and the victim of "prosecutorial misconduct." However, White House Press Secretary Kayleigh McEnany released a statement saying that "President Trump is gratified by today’s decision."

Continue Reading

Breaking Banner

‘They deserve it’: Republican strategist tells GOP it’s their own fault for going down with Trump because ‘they know better’

Published

on

Republican strategist Susan del Percio said that there is no excuse for GOP members who failed to do the right thing and fight back against President Donald Trump when they had the opportunity.

Speaking to MSNBC's Joy Reid Thursday, del Percio called Trump "the anchor" around the GOP's necks, "dragging them down."

"But, you know what, they deserve it," she continued. "There are Republicans out there that deserve this because they know better. They should have been better on impeachment. They should have been holding him accountable all along. Now they are scared and worried about themselves. Well, boohoo, you brought it on. there's no excuse."

Continue Reading
 

Breaking Banner

Trump officials demanded the Army ‘dig for misconduct’ to justify firing Lt. Col. Vindman

Published

on

This week, Lt. Col. Alexander Vindman willingly left the Army after decades of honorable service. He cited a concerted campaign of "bullying" from the highest branches of power in the United States, and now more details are becoming known.

A New Yorker report revealed that top aides to President Donald Trump were told that they needed to find dirt on Vindman that could justify the firing of the decorated war hero.

"Vindman expected to go to the National War College this fall—a low-profile assignment—then take another foreign posting," the New Yorker reported. "But, in a final act of revenge, the White House recently made clear that Trump opposed Vindman’s promotion. Senior Administration officials told [Defense Secretary Mark] Esper and Ryan McCarthy, the Secretary of the Army, to dig for misconduct that would justify blocking Vindman’s promotion. They couldn’t find anything, multiple sources told me. Others in the military chain of command began to warn Vindman that he would never be deployable overseas again—despite his language skills and regional expertise."

Continue Reading
 
 
You need honest news coverage. Help us deliver it. Join Raw Story Investigates for $1. Go ad-free.
close-image